KISUMU CRS

Site Details

LOCATION

New Nyanza Provincial General Hospital Grounds,

Off Kisumu-Kakamega Road

Kisumu, 40100

Get Directions

Site Type

CRS

CRS Coordinator

Rose Abwunza

rabwunza@kemricdc.org

254-721410654

CRS Leader

Beth Tippett Barr

hkc5@cdc.gov

254-722-772609

Site Trials

HIV Cure

Closed to accrual

A5354: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Will evaluate whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas of the body (reservoirs) and change how the immune system helps to control the virus.

This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs right away to see how this may change HIV’s impact on the body.

Hepatitis

HIV comorbidities and complications

HIV Cure

HIV Treatment

Tuberculosis

Closed to accrual

A5243: Non-US Genomic Sampling

Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing.

This is a study to collect blood and saliva samples from former and current participants in AIDS Clinical Trial Group (ACTG) studies at non-U.S. sites.

Hepatitis

Closed to accrual

A5379: B-ENHANCEMENT OF HBV VACCINATION IN PERSONS LIVING WITH HIV (BEe-HIVe): Evaluation of HEPLISAV-B

A5379 is a study looking at hepatitis B vaccination in adults living with HIV. Hepatitis B is a serious viral infection that affects the liver and is transmitted through blood and body fluids. The study will involve individuals who have received a previous hepatitis B vaccination but the vaccine did not respond well and individuals who have never received the vaccination. The study will take place both in the US and internationally. The study will compare how well an individual responds to the vaccine in different groups based on the type of vaccine and number of doses.